Eqis Capital Management buys $3,178,531 stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Eqis Capital Management scooped up 1,973 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 4, 2016. The investment management firm now holds a total of 26,670 shares of Johnson & Johnson which is valued at $3,178,531.Johnson & Johnson makes up approximately 0.20% of Eqis Capital Management’s portfolio.

Other Hedge Funds, Including , Bath Savings Trust Co reduced its stake in JNJ by selling 97 shares or 0.47% in the most recent quarter. The Hedge Fund company now holds 20,525 shares of JNJ which is valued at $2,446,170. Johnson & Johnson makes up approx 0.77% of Bath Savings Trust Co’s portfolio.Cacti Asset Management boosted its stake in JNJ in the latest quarter, The investment management firm added 4,455 additional shares and now holds a total of 264,411 shares of Johnson & Johnson which is valued at $31,512,503. Johnson & Johnson makes up approx 3.21% of Cacti Asset Management’s portfolio.Lvm Capital Management Ltdmi reduced its stake in JNJ by selling 20,467 shares or 17.72% in the most recent quarter. The Hedge Fund company now holds 95,066 shares of JNJ which is valued at $11,329,966. Johnson & Johnson makes up approx 3.58% of Lvm Capital Management Ltdmi’s portfolio.Lau Associates reduced its stake in JNJ by selling 1,175 shares or 2.77% in the most recent quarter. The Hedge Fund company now holds 41,277 shares of JNJ which is valued at $4,919,393. Johnson & Johnson makes up approx 5.02% of Lau Associates’s portfolio.

Johnson & Johnson opened for trading at $118.84 and hit $119.48 on the upside on Tuesday, eventually ending the session at $118.82, with a gain of 0.01% or 0.01 points. The heightened volatility saw the trading volume jump to 57,33,934 shares. Company has a market cap of $325,077 M.

On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.